Clinical Trials Logo

Urinary Bladder, Neurogenic clinical trials

View clinical trials related to Urinary Bladder, Neurogenic.

Filter by:

NCT ID: NCT00576823 Completed - Neurogenic Bladder Clinical Trials

Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology

Alfahydro
Start date: December 2007
Phase: Phase 3
Study type: Interventional

Primary objective was to determine efficacy of Alfuzosin in the treatment of children and adolescents 2-16 years of age with newly diagnosed or progressive hydronephrosis due to elevated detrusor Leak Point Pressure [LPP] of neuropathic etiology. Secondary objectives were: - To investigate the safety and tolerability of alfuzosin 0.2 mg/kg/day in children and adolescents, - To investigate the number of Urinary Tract Infection (UTI) episodes, - To investigate the pharmacokinetics of Alfuzosin (population kinetics).

NCT ID: NCT00549939 Completed - Clinical trials for Neurogenic Urinary Bladder

Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction

ALFACHIN
Start date: October 2007
Phase: Phase 3
Study type: Interventional

The primary objective of the study was to evaluate the efficacy of Alfuzosin in comparison to Placebo on the detrusor Leak Point Pressure (LPP) in children and adolescents 2-16 years of age with elevated detrusor LPP of neuropathic etiology and detrusor LPP ≥ 40 cm H2O. Secondary objectives were: - To investigate the safety and tolerability of two doses of Alfuzosin in comparison to Placebo in children and adolescents, - To evaluate the effects of the two doses of Alfuzosin in comparison to Placebo on: - Detrusor compliance, - Urinary tract infection, - To investigate the pharmacokinetics of Alfuzosin (population kinetics), - To evaluate the 12-month long-term safety of Alfuzosin 0.1 mg/kg/day and 0.2 mg/kg/day. The study consisted of 2 periods: - a 12-week double blind treatment period where patients were to receive either Alfuzosin 0.1 mg/kg/day or Alfuzosin 0.2 mg/kg/day or placebo then, - a 40-week open label extension treatment period where patients were to receive either Alfuzosin 0.1 mg/kg/day or Alfuzosin 0.2 mg/kg/day.

NCT ID: NCT00371631 Completed - Spinal Cord Injury Clinical Trials

Colonizing Neurogenic Bladders With Benign Flora

Start date: October 2006
Phase: Phase 1
Study type: Interventional

The purpose of the research is to determine whether we can get harmless bacteria to live in the bladders of persons with spinal cord injury who practice intermittent bladder catheterization. We will also look at whether having the harmless bacteria in the bladder prevents urinary tract infections from occurring.

NCT ID: NCT00340704 Completed - Bladder, Neurogenic Clinical Trials

PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder

Start date: April 2006
Phase: Phase 2
Study type: Interventional

Aims of this study is to characterize the pharmacokinetic/pharmacodynamic profile and evaluate the safety, efficacy and tolerability, of tamsulosin hydrochloride as treatment in children with a neuropathic bladder, over the course of 12 months of active treatment.

NCT ID: NCT00258089 Completed - Clinical trials for Urinary Tract Infections

A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections

Start date: June 1993
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the safety and effectiveness of oral levofloxacin (an antibiotic) with that of oral ciprofloxacin in the treatment of complicated urinary tract infections in adults.

NCT ID: NCT00221767 Completed - Clinical trials for Spinal Cord Injuries

Medico-economical Impact of the Brindley Neurosurgical Technique in France

BRINDLEY
Start date: June 2005
Phase: N/A
Study type: Interventional

Bladder dysfunction is a major problem in patients with complete spinal cord lesions. For patients presenting incontinence or risk for kidney, two major conventional alternatives are possible : conservative therapies (muscarinic receptor antagonists, vanilloids drugs and botulinum toxin in association with catheterization) and surgical techniques intervening in the nervous and urinary system. Among these last alternatives, the Brindley technique (anterior sacral root stimulation with posterior rhizotomy) is the only technique allowing for the restauration of bladder function, continence, and micturition. The purpose of the study is to compare the Brindley technique with the first conventional approach in France from a medical and economical point of view.